Shanghai Institute of Materia Medica of the Chinese Academy of Sciences have developed nitrogenous heterocyclic compounds described as as receptor-interacting serine/threonine-protein kinase 1 (RIPK1; RIP-1) inhibitors.
Researchers at Shanghai Institute of Materia Medica and the Wuhan Institute of Virology Chinese Academy of Sciences have prepared and tested cyclic bisbenzyl tetrahydroisoquinoline compounds reported to be useful for the treatment of fibrosis, viral infections and inflammatory disorders.
Shanghai Institute of Materia Medica of the Chinese Academy of Sciences has divulged aromatic heterocyclic compounds acting as lysine-specific histone demethylase 1A (KDM1A; LSD1) inhibitors reported to be useful for the treatment of cancer.
Researchers from Zhejiang University and Shanghai Institute of Materia Medica of the Chinese Academy of Sciences have reported the discovery of new phosphoinositide 3-kinase α (PI3Kα) inhibitors for the treatment of cancer.
In a study published in Cancer Cell on May 25, 2023, researchers from the University of Chicago and colleagues reported that the inhibition of YTHDF2, an immune suppressor protein, can be a valuable strategy to improve radiotherapy outcomes by overcoming resistance while enabling extra help from the immune system.
Shanghai Institute of Materia Medica of the Chinese Academy of Sciences and Tongji Hospital have disclosed sulfonylurea compounds acting as bifunctional epoxide hydrolase 2 (EPHX2; sEH) inhibitors reported to be useful for the treatment of heart failure.
Researchers at Shanghai Institute of Materia Medica of the Chinese Academy of Sciences have developed urea compounds containing 2-heteroaromatic ring substitution that act as cyclin-dependent kinase 9 (CDK9) inhibitors.
